Novo Nordisk said to have contracted Ypsomed to make next gen obesity drug’s pens
hapabapa/iStock Editorial via Getty Images
Novo Nordisk’s (NVO) (OTCPK:NONOF) contract with Swiss medical device maker Ypsomed (OTCPK:YPHDF) includes a deal to supply injection pens for Danish drugmaker’s next-gen obesity therapy CagriSema, Reuters reported Friday, citing a source familiar with the matter.
The report indicates the company’s long-term commercial plans for the once-weekly injectable, which is currently undergoing late-stage clinical development and expected to generate Phase 3 data this year.
CagriSema is designed by combining semaglutide, the active ingredient of Novo’s (NVO) popular weight loss therapy, Wegovy, with another compound mimicking a metabolic hormone called amylin.
Novo (NVO) expects it to generate 25% of average weight loss within a year, compared to Wegovy’s 15% and 20% achieved by its rival weight loss therapy Zepbound developed by Eli Lilly (LLY). Spokespersons for Novo (NVO) and Ypsomed (OTCPK:YPHDF) declined to comment.
Last year, Ypsomed (OTCPK:YPHDF) inked a long-term agreement to supply Novo (NVO) with autoinjectors designed to deliver self-administered therapeutics for multiple metabolic conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10